Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report

BACKGROUND: Patients with ovarian clear cell carcinoma (OCCC) have a poor prognosis because they show low sensitivity to platinum-based chemotherapy. New treatments for refractory OCCC are urgently needed. CASE PRESENTATION: We present a patient with refractory OCCC in whom conventional chemotherapy...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Ovarian Res
Egile Nagusiak: Lin, Yu-Chien, Wen, Kuo-Chang, Sung, Pi-Lin, Chou, Yu-Ting, Liew, Phui-Ly, Chen, Lin-Yu, Huang, Rui-Lan, Lai, Hung-Cheng, Chang, Lu-Te
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2020
Gaiak:
Case Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7725117/
https://ncbi.nlm.nih.gov/pubmed/33292376
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13048-020-00751-3
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak